User profiles for "author:Michael O’Dwyer"

Michael O'Dwyer

Haematology
Verified email at nuigalway.ie
Cited by 10716

[HTML][HTML] Glycosylation-based serum biomarkers for cancer diagnostics and prognostics

A Kirwan, M Utratna, ME O'Dwyer, L Joshi… - BioMed research …, 2015 - hindawi.com
Cancer is the second most common cause of death in developed countries with approximately
14 million newly diagnosed individuals and over 6 million cancer-related deaths in 2012. …

International evolution of fat, oil and grease (FOG) waste management–A review

T Wallace, D Gibbons, M O'Dwyer, TP Curran - Journal of environmental …, 2017 - Elsevier
In recent years, issues relating to fat, oil and grease (FOG) in sewer systems have intensified.
In the media, sewer blockages caused by FOG waste deposits, commonly referred to as ‘…

Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma

L Vincenz, R Jäger, M O'Dwyer, A Samali - Molecular cancer therapeutics, 2013 - AACR
Multiple myeloma is characterized by the malignant proliferating antibody-producing plasma
cells in the bone marrow. Despite recent advances in therapy that improve the survival of …

[HTML][HTML] Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

…, F Offner, J Mayer, M O'Dwyer… - … England Journal of …, 2015 - Mass Medical Soc
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

[HTML][HTML] Daratumumab plus lenalidomide and dexamethasone for untreated myeloma

…, H Quach, H Goldschmidt, M O'Dwyer… - … England Journal of …, 2019 - Mass Medical Soc
Background Lenalidomide plus dexamethasone is a standard treatment for patients with newly
diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. …

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival …

…, C Hulin, H Quach, H Goldschmidt, M O'Dwyer… - The Lancet …, 2021 - thelancet.com
Background In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months),
a significant improvement in progression-free survival was observed with daratumumab …

COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which …

…, Y Lai, J Wang, Z Liu, T Chen, A He, M O'Dwyer… - MedRxiv, 2020 - medrxiv.org
Background Excessive monocyte/macrophage activation with the development of a cytokine
storm and subsequent acute lung injury, leading to acute respiratory distress syndrome (…

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

…, S Padmanabhan, M O'Dwyer… - Blood, The Journal …, 2010 - ashpublications.org
NEDD8 activating enzyme (NAE) has been identified as an essential regulator of the NEDD8
conjugation pathway, which controls the degradation of many proteins with important roles …

Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes

…, Z Liu, T Chen, A He, M O'Dwyer… - Journal of Leucocyte …, 2021 - academic.oup.com
Excessive monocyte/macrophage activation with the development of a cytokine storm and
subsequent acute lung injury, leading to acute respiratory distress syndrome (ARDS), is a …

[BOOK][B] India as I Knew it, 1885-1925

M O'Dwyer - 1925 - books.google.com
… Irish Brigade (Dillon's, O'Brien's and FitzJames's Regiments) in the French Army. The records
of the Brigade show many generations of O'Dwyers or Dwyers (the O' was often dropped in …